Skinvisible, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 17, 2021 at 02:59 am IST
Share
Skinvisible, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was USD 287,099 compared to USD 110,970 a year ago. Operating income was USD 159,520 compared to operating loss of USD 12,762 a year ago. Net loss was USD 268,514 compared to USD 312,793 a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 0.07 a year ago. For the half year, sales was USD 299,150 compared to USD 118,613 a year ago. Operating income was USD 48,393 compared to operating loss of USD 142,754 a year ago. Net loss was USD 704,019 compared to USD 742,877 a year ago. Basic loss per share from continuing operations was USD 0.16 compared to USD 0.17 a year ago.
Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals Inc., is a pharmaceutical research and development (R&D) company. The Company is engaged in developing and patenting a polymer delivery system, Invisicare, and formulating over forty topical skin products. Its flagship product, Pivotal, is a patented polymer delivery system technology, Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied skin care products. Its patented technology has a formula and process for combining active ingredients with a delivery system that extends the duration of time the product remains on the skin and active. Invisicare is specifically formulated to carry water-insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. It is also exploring opportunities in medical markets outside the dermatology market.
SKINVISIBLE, INC. 
